The Cancer Letter

Inside information on cancer research and drug development

Clinical

Daily oral edoxaban met primary endpoint in Hokusai-VTE cancer study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Hokusai-VTE CANCER study evaluating oral edoxaban (known as Savaysa in the U.S. and Lixiana outside the U.S.) found edoxaban to be non-inferior to subcutaneous injectable LMWH dalteparin for the treatment of cancer-associated VTE or major bleeding.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Balance, gait negatively impacted after chemotherapy

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account